The case for & against
Bull & Bear analysis
Bearish
Pelthos Therapeutics Inc. (NASDAQ: PTHS) is an emerging player in the pharmaceutical sector, specifically focused on developing innovative treatments for dermatological conditions. The company's flagship product, Zelsumi, is designed to offer at-home treatment for molluscum contagiosum, catering primarily to pediatric patients. As it navigates the competitive landscape, Pelthos aims to leverage its unique product offerings and broaden its portfolio through strategic acquisitions and partnerships, positioning itself to meet the increasing demand for effective pediatric treatments.
Bull says
- ↑Q1 2026 revenue $10.7M, up 17% QoQ from $9.1M
- ↑Prescription units rose 25% YoY to 7,884 in Q1 2026
- ↑Expanded sales team by 14 reps, boosting market coverage
- ↑Two product launches (Zepi, Zeglize) slated for early/mid 2027
- ↑Cash runway bolstered by $50M debt financing and $32M cash
- ↑Strong liquidity and momentum factors underpin quality profile
Bear says
- ↓Q1 net loss $10.2M despite revenue growth, SG&A rising
- ↓EPS estimates cut for 2025–26, indicating falling analyst confidence
- ↓Short interest jumped 154%, highlighting skepticism over growth story
- ↓Increasing SG&A from sales expansion pressures cash flow
- ↓Negative dividend yield and low institutional ownership reflect low support
- ↓Small‐size factor and negative revisions suggest higher execution risks
Earnings Call · Q4 2025 · Mgmt. Guidance
Updated 08-18-2026bullish
Transcript signals
Bull points
- Overall, we had a very good fourth quarter and are delighted to report that net product revenue rose approximately 28%. from $7.1 million in the third quarter of 2025, which was our first quarter of launch, to $9.1 million in the fourth quarter of 2025.
- Netting this out, our quarterly net operating loss improved from a loss of 15.4 million during the third quarter to 12.0 million in the fourth quarter. And on an adjusted EBITDA basis, our EBITDA loss improved from a loss of 11.5 million in the third quarter to a loss of 9.0 million in the fourth quarter.
- Our balance sheet of December 31st was strong, with 18.0 million in cash and 8.9 million in accounts receivable, up from $14.2 million in cash and $8.0 million, respectively, at the end of the third quarter.
Read full transcript analysis ›